Figure 4. Effects of cetuximab, patritumab, and the combination of both drugs on the growth of DiFi-HRG tumor xenografts in vivo.

Nude mice with tumor xenografts established by subcutaneous injection of DiFi-Mock1 (A) or DiFi-HRG4 (B) cells were treated for 4 weeks with vehicle (control), cetuximab (1.0 mg/body), patritumab (1.0 mg/body), or both drugs, as described in Materials and Methods. Tumor volume was determined at the indicated times after the onset of treatment. Data are means ± SE from six mice per group. *P < 0.05 for comparison of the combination of both drugs with cetuximab alone or patritumab alone (Student's t test).